Cervical Intraepithelial Neoplasia Market Report 2026

The cervical intraepithelial neoplasia market size has grown strongly in recent years. It will grow from $1.14 billion in 2025 to $1.22 billion in 2026 at a compound annual growth rate (CAGR) of 7.8%. The growth in the historic period can be attributed to expansion of cervical cancer screening programs, increased detection of precancerous lesions, adoption of colposcopy-guided diagnostics, availability of excisional treatment devices, growing role of specialty gynecology clinics.

The cervical intraepithelial neoplasia market size is expected to see strong growth in the next few years. It will grow to $1.66 billion in 2030 at a compound annual growth rate (CAGR) of 8%. The growth in the forecast period can be attributed to increasing demand for early intervention strategies, rising adoption of biomarker-driven treatment decisions, expansion of community-based cervical care, growing focus on fertility-preserving treatments, integration of AI-assisted diagnostic imaging. Major trends in the forecast period include increasing adoption of biomarker-based triage methods, growing use of minimally invasive treatment devices, rising integration of digital colposcopy systems, expansion of outpatient cin treatment procedures, enhanced focus on early lesion risk stratification.

The rising occurrence of human papillomavirus (HPV) infection is expected to stimulate the expansion of the cervical intraepithelial neoplasia (CIN) market. Human papillomavirus infection is a widespread viral condition caused by a group of related viruses transmitted mainly through skin-to-skin or sexual contact, leading to warts, precancerous changes, and certain cancers, particularly affecting the cervix, anus, throat, and genitals. HPV infection is growing due to limited vaccination coverage in many regions, allowing continued transmission. Cervical intraepithelial neoplasia supports HPV infection evaluation by serving as a detectable precancerous lesion that reflects persistent infection and risk of disease progression. For example, in July 2025, Brieflands, a Netherlands-based medical and scientific publisher, reported that high-risk HPV prevalence increased from 12.78% in 2023 to 13.47% in 2024, representing an approximate 5.4% rise. Therefore, the rising incidence of HPV infection is boosting the growth of the cervical intraepithelial neoplasia market.

Leading companies operating in the cervical intraepithelial neoplasia market are focusing on advancing innovative solutions, such as non-invasive cervical cancer screening approaches, to support early detection, increase patient participation, and improve overall treatment outcomes. Non-invasive cervical cancer screening involves medical tests that identify precancerous or cancerous cervical changes without surgical intervention or tissue removal, commonly using techniques such as Pap smears, HPV DNA testing, or liquid-based cytology. For example, in September 2025, PHASE Scientific International Limited, a China-based biotechnology company, initiated a urine-based clinical study for cervical cancer (HPV) screening to progress non-invasive early detection strategies. The study is enrolling 17,000 women in China to validate non-invasive identification of cervical intraepithelial neoplasia (CIN) and cancer. Utilizing PHASiFY technology, the process concentrates HPV DNA more than 10,000 times, achieving 93.42% sensitivity and strong alignment with conventional swab testing, supporting WHO’s 90-70-90 elimination goals through convenient self-sampling, AI-supported colposcopy, and scalable public health implementation.

In January 2024, Becton, Dickinson and Company (BD), a US-based medical technology organization, partnered with Techcyte Inc. to introduce an AI-powered digital cervical cytology system for Pap testing. This collaboration aims to improve the identification and assessment of abnormal cervical cells by enabling earlier detection of precancerous conditions such as cervical intraepithelial neoplasia, while also increasing efficiency and consistency within cytology laboratories. Techcyte Inc. is a US-based provider of AI-driven digital pathology solutions, offering advanced image analysis platforms for laboratories and healthcare providers.

Major companies operating in the cervical intraepithelial neoplasia market are F. Hoffmann‑La Roche Ltd., Merck & Co. Inc., Pfizer Inc., Thermo Fisher Scientific Inc., Abbott Laboratories, GlaxoSmithKline plc., Quest Diagnostics Inc., Hologic Inc., QIAGEN N.V., Inovio Pharmaceuticals Inc., CooperSurgical Inc., PDS Biotechnology Corporation, Nykode Therapeutics ASA, Antiva Biosciences Inc., Genexine Inc., Papivax LLC, Zilico Ltd., TruScreen Group Limited, Arbor Vita Corporation, Frantz Viral Therapeutics Inc., Barinthus Biotherapeutics Inc.

Tariffs are influencing the cervical intraepithelial neoplasia market by increasing costs of imported colposcopy equipment, imaging systems, biopsy instruments, cryotherapy units, and electrosurgical devices. Hospitals and specialty clinics in North America and Europe are most affected due to dependence on imported diagnostic and treatment technologies, while Asia-Pacific faces higher equipment acquisition costs for expanding screening programs. These tariffs are raising capital investment requirements and slowing device replacement cycles. At the same time, they are supporting domestic device manufacturing, local assembly of treatment systems, and regional innovation in cost-effective cervical care technologies.

The cervical intraepithelial neoplasia market research report is one of a series of new reports that provides cervical intraepithelial neoplasia market statistics, including cervical intraepithelial neoplasia industry global market size, regional shares, competitors with a cervical intraepithelial neoplasia market share, detailed cervical intraepithelial neoplasia market segments, market trends and opportunities, and any further data you may need to thrive in the cervical intraepithelial neoplasia industry. This cervical intraepithelial neoplasia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Cervical intraepithelial neoplasia describes abnormal, pre-malignant changes occurring in the cells that cover the surface of the cervix, most commonly caused by persistent infection with high-risk strains of human papillomavirus, which disrupt normal cell growth, maturation, and structural organization. These atypical changes are limited to the cervical epithelial layer and do not invade deeper tissues, yet they pose a considerable risk of developing into invasive cervical cancer if they are not identified early and treated properly.

The primary types of cervical intraepithelial neoplasia include cervical intraepithelial neoplasia I, cervical intraepithelial neoplasia II, and cervical intraepithelial neoplasia III. Cervical intraepithelial neoplasia I represents mild cellular abnormalities of the cervix that may resolve without medical intervention. These conditions are diagnosed using techniques such as Pap smear testing, human papillomavirus testing, colposcopy, and biomarker triage. The treatment options include cryotherapy, loop electrosurgical excision procedures, cold knife conization, and immunotherapy. The distribution channels consist of direct sales, distributor and retail channels, and online sales, while the end users are hospitals, specialty clinics, diagnostic laboratories, and community health centers.

The cervical intraepithelial neoplasia market consists of sales of colposcopy devices, cryotherapy systems, laser ablation devices, loop electrosurgical excision procedure devices, biopsy tools, cytology testing kits, cervical imaging systems, and topical therapeutic agents. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.